Three advanced models of pharmacokinetics are described. In the fi rst class are physiologically based pharmacokinetic models based on in vitro data on transport and metabolism. The information is translated as transporter and enzyme activities and their attendant heterogeneities into liver and intestine models. Second are circulatory models based on transit time distribution and plasma concentration time curves. The third are fractal models for nonhomogeneous systems and non-Fickian processes are presented. The usefulness of these pharmacokinetic models, with examples, is compared.
INTRODUCTION
One of the most important outcomes in pharmacokinetic modeling is the ability to predict drug levels and/or dynamic behaviors of drug entities in the body. Another is the deduction of mechanistic insight into what events have happened. Sometimes the question is not how realistic the models are but what is their consistency and adequacy in making predictions. Most models are oversimplifi cations of the reality, but we have to start somewhere. It is certainly the hopes of pharmacokineticists that the models are easy to assemble, useful, and relevant.
Various approaches have emerged to predict blood/plasma and tissue concentration time profi les and/or provide mechanistic insight into what events have occurred. Compartmental approaches are the simplest and most widely used. The premise is based on venous equilibration and mass transfer into and out of compartments. In recent decades, however, modeling techniques have become more sophisti-cated. There is the departure from the compartmental modeling approach to physiological modeling in order to confer more signifi cance to the anatomy, fl ow, and discrete eliminatory and/or distributional organs in the body. 1 Among these more advanced models, 3 forms are described in this mini-review. First are the zonal and segmental physiologically based pharmacokinetic (PBPK) liver and intestinal models. Second is the circulatory model that can account for concentration differences within the vascular space or sampling compartment. Third is the fractal model that is relevant to systems with smaller dimensions, namely, fractal spaces or disordered systems. In this communication, we present the bases behind the models and the kind of information one can extract from them.
PHYSIOLOGICALLY BASED PHARMACOKINETIC ORGAN MODELS

Physiologically Based Pharmacokinetic Model for Organs
The physiologically based pharmacokinetic (PBPK) model is the simplest starting point in physiological modeling that relates organ or tissue structures to the physiology of the organ or tissue, and is based on the concept that compartments are homogeneous and well-stirred ( Figure 1 ). 2 Each organ or tissue of discrete volume is perfused by blood, a homogeneous medium that is connected to the central volume by fl ow. Venous equilibration is assumed, namely the venous drug concentration is in equilibrium with that in the organ. 2 , 3 Then organ-tissues are interconnected by the circulation and are put in place anatomically. 1 Several important variables, including blood fl ow, plasma and red blood cell binding and transporter and enzyme activities have been identifi ed as the determinants of organ clearance. [3] [4] [5] [6] [7] [8] Simple PBPK models have been applied to describe data from the liver, 2 , 3 , 9 kidney, [10] [11] [12] intestine, 13 , 14 and whole body. 1 , 15 , 16 Several important variables, including blood fl ow, plasma and red blood cell binding, and transporter and enzyme activities have been identifi ed as the determinants of organ clearance. [3] [4] [5] [6] [7] [8] The PBPK model for the liver is based on the liver as the only eliminating organ in a situation akin to the recirculating perfused rat liver preparation ( Figure 1A ). 2 The model has been extended to describe metabolism, excretion, and transport. 8 Processes describing carrier-mediated or passive transport are denoted by the infl ux and effl ux clearances (CL infl ux and CL effl ux ) representing the activities of the basolateral transporters and passive diffusion. Sinusoidal transporters such as the sodium-dependent cotransporting polypeptide (NTCP), the organic anion transporting polypeptides (OATPs), and the organic anion (OAT2) and cation (OCT1) transporters facilitate infl ux ( Figure 2 ) . 5 , 7 , 9 Basolateral effl ux at the lateral membrane occurs via MRP3 or MRP4, multidrug resistanceassociated transporters 3 and 4 ( Figure 2 ). [17] [18] [19] Biliary excretion is mediated via canalicular, ATP binding cassette (ABC) transporters such as the multidrug-resistance protein 1 (MDR1), also known as the P-glycoprotein (Pgp), the multidrugresistance -associated protein 2 (MRP2), the bile salt export pump (BSEP), and breast cancer resistance protein (BCRP). In addition, drugs may be metabolized by phase I enzymes such as the cytochrome P-450s, and phase II enzymes such as the sulfotransferases (SULTs), UDP-glucuronosyltransferases (UGTs), and glutathione S-transferases (GSTs). The activities or the intrinsic clearances for biliary excretion by the ABC canalicular transporters and enzymes are denoted by the secretory (CL int,sec ) and metabolic intrinsic clearance (CL int,met ), respectively ( Figure 2A ) . 2 , 5 , 7 , 8 , 20 Ordinarily, in vitro transport and metabolic studies provide estimates of the V max (maximum velocity) and K m (Michaelis-Menten constant) for uptake and metabolism. The ratio of V max /K m for uptake then furnishes estimates of the infl ux clearance (CL infl ux ), whereas that for V max /K m from metabolic studies provides the metabolic intrinsic clearance, CL int,met . 2 , 21 , 22 It is often diffi cult to estimate the CL int,sec since the drug needs to have entered the cell and the (unbound) cellular concentration needs to be known to relate to the biliary excretion rate.
The advantage of modeling is that mathematical expressions that relate to fl ow, binding, and transporter and enzymatic activities are derived by matrix inversion for linear conditions. Solutions for clearances were found for the liver Figure 1 . The simple physiologically based pharmacokinetic model (PBPK) (A) and zonal liver model (ZLM) (B). In the PBPK model (A), the liver compartment consists of the liver blood, tissue and bile compartments. Infl ux (CL infl ux ) and effl ux (CL effl ux ) clearances, as well as the metabolic (CL int,met ) and secretory (CL int,sec ) intrinsic clearances regulate levels of drug in tissue (D L ), plasma (D P ) and reservoir (D R ). M LB is total amount of metabolite formed, including the amounts of metabolite in reservoir, bile, and liver tissue as well as those for subsequently formed metabolites; Q L and Q bile are the liver blood fl ow and bile fl ow rates, respectively. In the ZLM (B), the liver is divided into 3 zones (PP zone or zone 1, middle zone or zone 2, and PV zone or zone 3) according to the hepatic microcirculation. Subscript " i " denotes the infl ux (CL infl ux,i ), effl ux (CL effl ux,i ) and metabolic (CL int,met,i ) and secretory (CL int,sec,i ) intrinsic clearances in different zones. The sum of the all the activities in the zonal compartments provides the total intrinsic clearance for transport or metabolism. The models may further be modifi ed to describe red blood cell (rbc) partitioning and binding to plasma proteins such as albumin (alb), expressed as the unbound fraction in plasma, f p . Figure 2 . Schematic diagram of transport and metabolism of drugs in the hepatocyte that shows infl ux transporters, such as OATP, NTCP, OAT2, OCT1, and MCT2 at the sinusoidal membrane, and effl ux transporters such as MRP3, MRP4, and MRP6 at the basolateral membrane, and effl ux transporters, such as Pgp or MDR1, MDR3, MRP2, BSEP, BCRP at the canalicular membrane. The enzymes, such as CYP, UGT, SULT, and GST are present to mediate intracellular metabolism (reproduced with permission). 7 Set text for defi nition of terms.
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PBPK model ( Figure 1A ) . As shown below, the metabolic (CL liver,met ), biliary (CL liver,ex ), and total hepatic (CL liver,tot ) clearances relate to CL infl ux , CL effl ux , CL int,sec , CL int,met , fl ow (Q L ), and the unbound fraction in blood (f b ). 20 
CL
It is readily seen that the total clearance (CL liver,tot ) is the sum of the metabolic (CL liver,met ) and biliary (CL liver,ex ) clearances. (4) From perfusion or in vivo studies, CL int,sec may be estimated indirectly from Equation 4 when the ratio of the metabolic/ biliary clearance, as well as CL int,met , is known. With knowledge of the binding parameter, f b (unbound fraction in blood, estimated as the unbound plasma fraction, f p , divided by the blood to plasma concentration ratio, [C blood /C plasma ]), the only unknown left is the effl ux clearance (CL effl ux ). The parameter may be estimated from fi tting.
Zonal Liver Model
It is notable, however, that hepatic enzymes and transporters are distributed in varying abundances among hepatocytes or zonal regions ( Table 1 ) . [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] The appropriate modifi cation to accommodate this complexity is use of a zonal liver model (ZLM), the expanded counterpart of the PBPK model ( Figure 1B ) . 7 , 34 Zones of the liver are denoted as subcompartments to include heterogeneity of transporters and enzymes. The ZLM describes zones 1, 2, and 3 that correlate to the periportal, midzonal, and perivenous zones of the acinus, the simplest microcirculatory unit ( Figure  1B ). 40 As may be envisioned, transporters are mostly distributed evenly; whereas many enzymes are not ( Table 1 ) . In the ZLM, the total activity for each sinusoidal infl ux or effl ux transporter is simply the sum of those from individual zonal regions; the same may be said about the enzyme for metabolic activity and the canalicular transporter for excretory activities. For evenly distributed activities, the zonal activity for each acinar region is approximated by dividing the total transporter activity or intrinsic clearance for transport by 3. For uneven distributions, the zonal activity may 34 The immunoblots on protein levels of Oatp1a4 for uptake and Pgp for excretion suggest lack of zonal transport of digoxin among rat periportal and perivenous rat hepatocytes. 34 With these background information on hand, the fi t of the digoxin data arising from rat liver perfusion experiments, performed in the absence and presence of albumin and red cells in perfusate, to the PBPK model showed excellent results ( Figure 3 ). 34 From modeling, the ratedetermining step in controlling digoxin clearance was discerned to be protein binding and not enzyme or transporter activity. Additional information on the expression of protein levels of enzymes and transporters and their acinar distributions served as vital data for the ZLM. With the known perivenous distribution of Cyp3a2 (expressed as a percentage of total CL int,met ) and the even distribution of transporters (Oatp1a4 and Pgp) for the ZLM, the fi t only improved nominally, showing that heterogeneity is not an important factor, since digoxin is a poorly cleared by the rat liver.
Estradiol 17 b D-glucuronide (E 2 17G)
The contrasting example is E 2 17G, a model substrate that is highly cleared in the rat liver because of rapid sinusoidal and canalicular transport by the Oatp1a1, Oatp1a4, and Oatp1b2, and Mrp2, respectively, and sulfation by estrogen sulfotransferase (Sult1e1). 9 The 3-sulfated metabolite, E 2 3S17G, fails to traverse the basolateral membrane for both infl ux and effl ux, but undergoes desulfation and therefore futile cycling with E 2 17G. Avid excretion of E 2 3S17G and E 2 17G occurs with Mrp2. In Wag/Rij rats that developed liver metastasis upon intraportal injection of CC531 colon adenocarcinoma cells, sinusoidal transporters, Oatp1a1 and Oatp1b2, were reduced (40% loss), whereas Sult1e1 was induced (40%) compared with those in the sham-operated livers. 9 These occurrences were well described by the PBPK model fi t of data obtained in liver perfusion studies ( Figure 4 ). 9 The reduction in sinusoidal activity proved to be irrelevant since basolateral entry of E 2 17G was so rapid (> 40× blood fl ow rate) that, despite a reduction of transport with tumor, uptake of E 2 17G was maintained rapid enough (> 20× blood fl ow rate). In contrast, induction of Sult1e1 in tumor livers increased E 2 3S17G formation, and evoked compensatory decreases in the biliary excretion of E 2 17G, although the activities of Mrp2 that excretes both E 2 17G and E 2 3S17G were unchanged ( Figure 4A ). 9 These observations highlight the interplay between the enzyme and canalicular transporter; increased metabolism evoked a compensatory decrease in excretion even though Mrp2 activity remained unchanged. The zonal Sult1e1 activities toward estrone sulfation were known 29 ; the ratio of Sult1e1 activities in periportal versus perivenous hepatocytes was 1:4. Taking the assumption that the same existed for E 2 17G sulfation, enzymic heterogeneity of Sult1e1 was predicted as an important rbc-alb-perfused (with binding) livers. Dg2 (▲) represented summed amounts of all of the metabolites in reservoir and bile (% dose), but not those in liver (> 40% dose). Therefore, the total amount of metabolite (Dg2) was predicted rather than fi tted, and the predicted amount of metabolite formed (Dg2 total ) was underestimated since Dg2 amounts in liver was not accessible. Reproduced with permission. 34 
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factor in E 2 17G elimination. This is because E 2 17G is highly cleared by the rat liver. 7
Intestinal Models
Physiologically based models have been used to describe data for intestinal absorption, secretion, and metabolism. The simple, physiologically based or traditional model (TM) was fi rst used to explain the metabolism of morphine to morphine 6-glucuronide in the perfused small intestine preparation ( Figure 5 ) . The TM was then modifi ed to the segregated fl ow model (SFM) ( Figure 5 ) in order to explain the preferential metabolism of morphine, given orally versus systemically 13 ; the phenomenon is known as routedependent intestine metabolism. 46 The SFM entails a split flow to the enterocyte region and the remainder of the intestine, and suggests that a low proportion of the intestinal blood supply (5% to 30%, assigned as 10% for sake of simplicity) enters the enterocyte or active region for absorption, effl ux, and metabolism. The SFM is superior to the TM in explaining the absence and presence of morphine glucuronidation when given systemically and orally, respectively, to the perfused rat intestine preparation ( Figure 6 ). 13 , 46 As in the liver, intestinal enzymes and transporters are involved ( Figure 7 ), and these are also heterogeneously distributed among segments ( Table 2 ) . [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] Segmental and segregated fl ow models (STM for segmental, tradition model, and SSFM for segmental, segregated fl ow model) have been applied to incorporate heterogeneity in fl ow, enzymes, and transporters along the small intestine ( Figure 8 ). 63 Basically, the TM and SFM are expanded to 3 segmental regions receiving parallel artery blood supply. The SSFM aptly explains route-dependent intestinal elimination and incorporates segmental distribution of enzymes and transporters in drug absorption. Heterogeneity was noted for Cyp3a and Pgp, a major contributor for digoxin effl ux, among the segments ( Figure 8 ), although both Pgp and Cyp3a (mostly Cyp3a9 and Cyp3a62 in intestine, 64 detected by the antibody) were induced by pregnenolone 16 a -carbonitrile (PCN), a ligand of PXR, the pregnane X receptor. Digoxin removal was found to be mediated only via Pgp in the perfused rat intestine since levels of Cyp3a2 are low in the intestine. 64 The total activity (aggregate of the relative intensities of all the segments) may be found by summation of protein/segment × intensity/ m g protein; then the relative intensity for duodenal, jejunal, or ileal segment, divided by the total relative intensity of the intestine, would provide the E273 fraction of the total activity, and yields the fractional intrinsic clearance for metabolism or excretion. Upon modeling fi rst with the SFM with an unstirred water layer exiting in the lumen, the intravenous and oral data of digoxin were predicted well by the SFM ( Figure 9 ). When the heterogeneity of Pgp was factored in for purposes of simulation, the prediction was only slightly improved, since digoxin is poorly cleared by Pgp and metabolism was virtually absent in the rat intestine. In this case, the SFM or even TM suffi ces and the SSFM need not be evoked. 34 These examples are successful accounts that data on transporters and enzymes, with and without induction, may be explained by data in the perfusion system, and are adequately described by physiologically based and segmental models.
CIRCULATORY MODELS
Although circulatory models were introduced into pharmacokinetics more than 25 years ago, 65 , 66 less than ~1% of the models used since then analyze clinical pharmacokinetic data that obey a circulatory structure. The relevance of circulatory models in whole-body pharmacokinetics appears justifi ed since the underlying transport processes are primarily advective transport to the organs or tissues and diffusion within organs, and one could argue that the fundamental role of circulatory drug transport should imply a recirculatory model. However, the decisive question is not the truth of the models but their adequacy for solving a certain task, or according to an often-quoted statement by George Box: " all models are wrong but some are useful " ( Robustness is the Strategy of Scientifi c Model Building , 1979) ( " wrong " in the sense that all models are simplifi cations of reality). Thus, the practical question is: why and when are circulatory models more useful than traditional models? The rationale behind the use of mammillary compartmental models in pharmacokinetics is the modeling of drug distribution in the body. A drawback of conventional models is that these compartments lack physiologic reality, and distribution parameters cannot be readily interpreted in terms of underlying transport mechanisms, ie, advective transport by blood fl ow (vascular mixing), transcapillary transport (permeation), and tissue-binding kinetics. Thus, these models fail to describe the time course of drug concentration within the fi rst 2 minutes following bolus injection (including the role of the lung) because of the assumption of instantaneous mixing in the central compartment. In contrast, recirculatory models with compartmental subsystems adequately characterize the initial mixing phase and the pulmonary fi rst-pass effect, and are of special importance for fast-acting drugs like intravenous anesthetics. In addition to intravascular mixing, a minimal circulatory model in which all organs of the systemic circulation are lumped into one heterogeneous subsystem may also account for transcapillary transport and intratissue diffusion of drugs, and are particularly useful to evaluate the distribution kinetics of drugs under the infl uence of disease states. 
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A condition that limits the complexity of models of solute distribution in the body is that they must be theoretically and practically identifi able while remaining consistent with known physiology. An implicit assumption in the use of the term " circulatory " pharmacokinetic models is that the parameters can be estimated on the basis of plasma concentration -time data, and are readily applicable to clinical data. The so-called PBPK models, in contrast, also have a circulatory structure but are typically too complex for identifi cation on the basis of plasma concentration time data alone. 67
Initial Distribution
Circulatory models have been successfully used to evaluate the distribution kinetics of fast-acting drugs, and to relate them to the onset and offset of action. Thus, it is now well recognized that modeling of drug distribution kinetics within the fi rst 2 minutes (front-end kinetics) determines the induction dose of intravenous anesthetics. 68 , 69 A recirculatory model with a chain of compartmental subsystems that adequately characterizes pulmonary fi rst-pass distribution and intravascular mixing has been applied to analyze the kinetics of inulin, antipyrine, lidocaine, and thiopental. [70] [71] [72] This model uses plasma concentration time data, in the absence of destructive sampling, to describe the effect of changes in hemodynamics attributable to drug interaction 71 or hemorrhagic shock 73 on whole body pharmacokinetics. In a PK/PD analysis of rocuronium, Kuipers et al 74 showed that circulatory models accounted for the effect of cardiac output and allowed an improved estimation of pharmacodynamic parameters. Similar circulatory models with compartmental subsystems have been applied to propofol 69 , 75 and fentanyl. 76 A prerequisite of such studies is a high frequency of arterial blood sampling during the fi rst minutes after rapid drug injection and the concomitant administration of a vascular marker, indocyanine green (ICG). From the ICG disposition data, cardiac output and blood volume can be estimated. Although the latter is the initial mixing volume of the drug, this process does not occur instantaneously, with the consequence that the initial distribution volume (well-mixed plasma compartment) as defi ned in mammillary compartmental models is fi ctitious. It is often overlooked that for highly extracted drugs this simplifi cation may lead to errors in clearance estimation. 77 It should be noted that instantaneous initial mixing is also an implicit assumption of the use of monotonically decreasing disposition Figure 8. Heterogeneity of Pgp (left panel) and Cyp3a (right panel), detected in enterocyte membrane fragments along segmental regions of the rat small intestine by Western blotting. S1 denotes the duodenum, S2, the proximal jejunum of equal length as S1; S8 is the distal ileum, and S3-S8 are segments of equal lengths, with S2 -S7 representing the jejunum. Both Pgp and Cyp3a were induced by PCN (pregnenolone 16 acarbonitrile), a ligand of the pregnane X receptor, PXR. The symbol " * " denotes P < .05. Taken from reference 59, with permission.
curves (eg, multiexponential functions). If drug input is slower than the initial distribution process (short-term infusion), the effect of the latter is reduced or lost. Thus, simpler recirculatory models and less frequent sampling are suffi cient in this case, 78 , 79 especially when an independent estimate of cardiac output is available.
Circulatory Models with Heterogeneous Subsystems
Because circulatory models with compartmental subsystems can be described by a set of ordinary differential equations simplifi es mathematical modeling, since most available software for parameter estimation allows model representation by differential equations. This does not hold, however, for nonhomogeneous subsystems, ie, the modeling of dispersion and diffusion processes. A mathematical tool that is independent of the underlying specifi c structural model can be found in the theory of residence or transit time distributions. The equation for the arterial concentration -time curve after rapid bolus injection (dose D iv ) of the drug is available in the Laplace domain as a function of transit time densities (TTD) across subsystems, the pulmonary circulation, f^p(s), and the systemic circulation, f^s(s) 78 :
where Q body is cardiac output and E sys the extraction ratio of drug in the systemic circulation ( Figure 10 ) . A method of numerical inverse Laplace transformation must be implemented in a nonlinear regression software for parameter estimation and model simulation. Independent of its use in data analysis, a stochastic circulatory model can serve as a basis for developing a mechanistic approach to drug distribution in the body. 80 It can be shown that vascular mixing is a result of mechanical dispersion in the microcirculatory network. An appropriate TTD of the vascular marker is the inverse Gaussian density, 81 , 82 known as the fi rst passage time of a random walk process with drift. Since the latter evolves as a solution to the convection-dispersion equation, 83 it is not surprising that circulatory mixing models can also be based on this equation. 84 , 85 The circulatory minimal model ( Figure 10 and Equation 5) has been successfully applied to the data of ICG and unbound drugs, 82 including sorbitol ( Figure 11 ). Processes that govern tissue distribution kinetics of drugs, such as capillary permeation and intratissue diffusion (and/or binding), further increase the relative dispersion of transit times. 82 , 86 While the mean Figure 9 . Fit of the intestinal perfusion data of digoxin (Dg3) for intravenous (A) and oral (B) dosing, with (᠉, blue symbols) and without (᠉, red symbols) PCN treatment, to the SFM; an unstirred water layer needed to be added to the SFM model. 59 Avid secretion of digoxin (▲,▼) but little digoxin metabolism to DG2 ( ■ ) was observed. Predictions from the SFM matched the observations on PCN-treated ( − − − − − ) and control ( − − − − ) experimental data well. The symbol " * " denotes P < .05. Taken from reference 59, with permission. 
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transit time and fl ow determine the distribution volume, the relative dispersion of TTD and fl ow determine distribution clearance. 78 , 82 , 87 The model describes the change from fl owto diffusion-limited distribution as a continuous transition. 87 Thus, apart from its ability to describe initial mixing, a circulatory model provides a framework that allows for quantitative assessment of processes governing distributional equilibrium in the body. It can be used to defi ne the total distribution clearance of a drug as a parameter of distribution kinetics, which has a clear physical meaning. 78 , 82 
Nonhomogeneous Sampling Compartment
Since circulatory models can account for concentration differences within the vascular space, they are useful for the analysis of plasma concentration -time data obtained at different sampling points, eg, when portal and systemic blood samples were simultaneously taken to evaluate intestinal absorption 88 and/or to characterize the role of the liver. 89 The transient concentration difference between arterial and peripheral venous blood concentration, on the other hand, have to be taken into account in PK/PD modeling.
FRACTAL PHARMACOKINETICS
Kinetic processes are traditionally interpreted with classical kinetics that is quite satisfactory for reactions and processes in well-stirred media. The kinetics of diffusion-controlled processes and reactions in 3-dimensional homogeneous systems obey the classical laws of diffusion where the rate constant of the process is linearly proportional to the diffusion coeffi cient. However, this proportionality is no longer valid for systems with smaller dimensions, namely, fractal spaces or disordered systems, since the laws of transport are different in these media. Accordingly, fractal kinetics has been developed since classical kinetics has been found to be unsatisfactory under dimensional constraints, eg, phase boundaries, understirred media, or membrane reactions.
Classical models used in biopharmaceutics, pharmacokinetics, and pharmacodynamics rely on the concept of homogeneity . For example, the compartments in multicompartmental PK/PD models are considered homogeneous and well mixed. However, the most compelling feature of physiological systems is their complexity. The assumptions of homogeneity and well-stirred media are contrary to the evidence provided by the anatomical and physiological complexity of the human body. Thus, many diffusion-controlled drug processes take place in understirred media, where the rate constant of the process is not linearly proportional to the diffusion coeffi cient. A diffusion process under such conditions may be highly variable since the laws of transport are different in these media. A general well-known result is that in constrained spaces, diffusion is slowed down and follows an anomalous pattern. A better description of transport limitations can be based on the principles of diffusion in disordered media. 90 Thus, concepts from fractal geometry 90 and fractal kinetics 91 , 92 can be used to achieve a more realistic modeling of the complex and the kinetically heterogeneous phenomena. 93 Table 3 provides a list of the basic classical and nonclassical considerations accompanying the study of the in vitro and in vivo processes. A review article focusing on the homogeneous and heterogeneous approaches used for the description of the various phenomena involved in the time-course of drug through the body has been published recently. 94 A brief description of the concepts of fractals and fractal kinetics are given here along with various applications in the fi elds of biopharmaceutics and pharmacokinetics.
Fractal Models for Drug Release, Dissolution, and Uptake
The assumptions of homogeneity and/or well-stirred media in the gastrointestinal (GI) tract are contrary to the evidence given the anatomical and physiological complexity of the Figure 11 . Fits of the circulatory model ( Fig. 10 and Equation 5 ) to sorbitol plasma concentration -time data as observed for a 1-minute infusion 0.8 g sorbitol in a human volunteer under control conditions ( ▀ ) and after infusion of orciprenaline (᠉) leading to a 50% increase in cardiac output (Weiss M, Huebner G, Sziegoleit W, unpublished data, 2000). The AAPS Journal 2007; 9 (2) Article 30 (http://www.aapsj.org).
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GI tract. All processes related to GI drug absorption, ie, drug release, dissolution, transit, and uptake are heterogeneous since they take place at interfaces of different phases (solidliquid or liquid-membrane) under topological constraints (variable and understirred conditions). As the drug moves down the intestine, the fl ow is forced in the narrow and understirred spaces of the colloidal contents and therefore friction becomes more important than intermolecular diffusion. The characteristics of this type of fl ow have been studied with Hele-Shaw channels ensuring a quasi 2-dimensional space using miscible fl uids of different viscosities. 95 , 96 These studies revealed that viscous, fractal fi ngers are formed under these topological constraints, which have also been observed in experiments dealing with the secretion of HCl and its transport through the mucus layer over the surface epithelium under in vitro and in vivo conditions. 97 , 98 In light of these observations, drug absorption phenomena have been interpreted in terms of fractal concepts. 99 It was proposed that the transit, dissolution, and uptake of drug under the heterogeneous GI conditions obey the principles of fractal kinetics. 92 For this type of kinetics, the rate " constants " depend on time:
where k is the rate coeffi cient, k 0 is a constant, and the exponent, l , is different from zero and is the outcome of 2 different phenomena: the heterogeneity (geometric disorder of the medium) and the imperfect mixing (diffusion-limit) condition. In this vein, the " absorption rate coeffi cient, " which is compatible with the time-dependent character of the process, was proposed to replace the classic notion of " absorption rate constant. " 99 Reports of 2 studies showed that time-dependent absorption models were used to interpret the GI absorption of cyclosporine A 100 and propanolol. 101 Moreover, Monte Carlo techniques that incorporate the heterogeneous features of the GI wall structure and of the drug fl ow have been used to characterize the intestinal drug transit, dissolution, and uptake. 102 , 103 It is also worthy to mention recent fi ndings on the chaotic nature of the gastric myoelectrical complex. 104 Thus, the frequently observed high variability in gastric emptying data should not be attributed exclusively to the classical randomness of rhythmic electrical oscillation in the stomach. Plausibly, one can argue that this will have an immediate impact on the absorption of highly soluble and highly permeable drugs from immediate release formulations since their absorption is controlled by the gastric emptying rate.
In the fi elds of drug release and dissolution, several studies support the heterogeneous features of these processes. The empirical, wide, and successful application of the Weibull function 105 (Equation 7) in dissolution studies have been justifi ed theoretically on the basis of fractal kinetics considerations. 106 Lansky and Weiss [107] [108] [109] introduced the concept of the nonconstant fractional dissolution rate and provided an index to quantify heterogeneity for various dissolution models. Also, a population growth model of dissolution based on a difference equation was developed. 110 The derivation of the recurrence equation of this model does not rely on Fick ' s fi rst law of diffusion and the time continuity assumption and it has been used to explain classical and nonclassical (supersaturated) dissolution data. 110 , 111 Diffusioncontrolled drug release has also been studied in Euclidean and fractal geometries using Monte Carlo techniques. 112-119 It was found 113 , 114 that the Weibull model (which is the exponential of a power law [ie, a stretched exponential function]) is:
where M t and M ∞ are the amounts of drug released at times t and infi nity, respectively, and a and b are constants. The equation describes quite well experimental and computergenerated data using Monte Carlo techniques; also, a physical meaning for a and b in Equation 7 was provided recently. 120 The exponent of time b originates from the fact that a depletion zone is created gradually near the boundaries of the release device, and thus, the concentration in the device is not uniform.
Pharmacokinetics, Drug Metabolism, and Disposition
In contrast to classical pharmacokinetics in which a compartmental system is made up of a fi nite number of compartments, each being homogeneous and well mixed and interacting by exchanging material, the essential materials and drugs in the human body are transported through spacefi lling fractal networks of branching tubes while the internal surface areas of organisms for material exchange are " maximally fractal. " 121 , 122 These observations prompted Karalis et al 123 to conceive the body as a fractal object with an infinitely high surface-to-volume ratio in order to interpret the nonphysiological values (>70 L) of the apparent volumes of distribution of drugs. The effective exchange area in the internal structure of the body was linked to the so-called " fractal volume of drug distribution, " 123 which was recently associated with the body surface area used in dosage regimen design. 124 The clearance analog, called " fractal clearance, " was also defi ned 125 ; both novel parameters were used in quantitative structure pharmacokinetic relationships. [125] [126] [127] Additionally, the use of the scaling laws describing the fractal-like architecture of the arterial and venular trees enabled the development of a physiologically based model of 1-dimensional tube for the transport of materials in the circulatory system. 128 Figure 12 shows the geometrical transformation of the dichotomous branching network to an equivalent 1-dimensional tube, which corresponds to the arterial, venular, and pulmonary trees successively. A dispersion-convection partial differential equation with constant coeffi cients was used to describe the heterogeneous concentration profi le of an intravascular tracer (indocyanine green) in the vascular tree. This model was further applied to the estimation of recirculatory parameters. 85 The deterministic defi nition of a compartment refers to a kinetically homogeneous amount of material. The equivalent stochastic defi nition is that the probability of a unit participating in a particular transfer out of a compartment, at any time, is the same in all units in the compartment. 93 This allows us to formulate stochastic compartmental models based on probabilities of transfer that can capture heterogeneity in pharmacokinetics. A model of this type has been developed for cyclosporine. 129 In parallel, the simplifi ed notion of the classical homogeneous compartments used in pharmacokinetics has been questioned in the literature [130] [131] [132] [133] [134] and attempts have been made for a more realistic description of the heterogeneous features of drug distribution in the body. Two approaches, based on fractal kinetics principles, have been used to describe the pharmacokinetics of Ca 2+ and amiodarone in deep tissues. 134 , 135 The kinetics of drug metabolism in the human body is classically analyzed with the Michaelis-Menten (MM) formalism. Normally, the derivation and application of the MM equation presuppose that the substrate (drug)-enzyme reaction takes place in a well-stirred medium. However, many enzymes are now known to be localized within 2-dimensional membranes or quasi 1-dimensional channels. Thus, several approaches have been proposed for the analysis of the enzyme-catalyzed reactions under topological constraints. [136] [137] [138] Also, Monte Carlo simulations were used for the study of the enzymatic reaction in 2-dimensional lattices. 139 It was found that the micro-constant associated with the formation of the substrate-enzyme complex is a time-dependent reaction coeffi cient, ie, it crosses over from a constant region at short times to a power law decrease at longer times. 139 Fuite et al 140 were the fi rst to incorporate a " fractal compartment " in a physiologically based pharmacokinetic model in order to explain the unusual nonlinear pharmacokinetics of mibefradil ( Figure 13 ). This " fractal compartment " was associated with the fractal structure of the liver, which dictates the unusual kinetics of mibefradil. Monte Carlo simulations of the enzymatic reaction in a 2-dimensional lattice were also performed under conditions that mimic the in vivo recirculation of the reactant species, ie, drug and metabolite. 141 A modifi ed version of the MM equation was derived from the Monte Carlo simulations and used to explain mibefradil pharmacokinetics. Recently, fractal MM kinetics under steady-state conditions was also applied to mibefradil pharmacokinetics. 142 Chelminiak et al 143 applied the theory of networks to investigate the effects of diseased states of the liver on its ability to clear a drug from the plasma. By varying the number of links and traps of the random network, different disease states of the liver related to vascular damage were simulated. This study is the fi rst to describe the liver as a network of catalytic enzymes and attempts to quantify the ability of the liver to metabolize drug molecules under a range of conditions that refl ect both normal and pathological conditions. 143 
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COMPARISON OF MODELS
We have described 3 advanced models that may use different forms of data and display different types of information. PBPK models are highly correlated with physiologically relevant structures and anatomical placements of organs in the body. The PBPK and ZLM for the liver and the SFM and SSFM for the intestine are structurally based models that further relate to zones of the liver and segments of the intestine in housing transporters and enzymes. These models use data on transporters and enzymes to refl ect knowledge pathways controlling the time-and space-events in the organ and provide data that are more mechanistically based. The models relate to processes mediated by transporters, enzymes, fl ow, red cell, and protein binding, provide mechanistic information on the rate-limiting step, appraise changes in transporters or enzyme, and explain the interplay of transporters and enzymes. The physiological variables: weights, lengths, physiologic volumes, and attendant blood fl ow to each subcompartment (zone/segment) all need to be considered. Heterogeneity in transporters and enzymes among different compartments and homogeneous fl ow are adequately addressed. Changes in transporters and enzymes, as noted via protein characterization, are used for prediction in the physiologically based models, thereby providing mechanistic insight to biological events occurring within eliminating organs.
The PBPK model emphasizes an instantaneous equilibrium between spaces for distribution, transfer, and elimination. However, equilibration within each subcompartment and the blood compartment is deemed as instantaneous. This is not achieved in reality. In circulatory models, this assumption does not need to be made. The circulatory and fractal models relate more to stochastic events and incorporate heterogeneity in fl ow and organ structure. The model is able to account for the lack of immediate equilibration in blood, even at different locales and other tissue compartments. Circulatory models are more relevant if the goal of the study is to examine problems of drug distributional kinetics, eg, effects of changes in cardiac output, capillary permeability, tissue binding, and of concentration gradients within the circulation. Since the validity of a model is solely determined by the modeling objectives, traditional models should be suffi cient in all other cases. The circulatory model has been developed for situations in which only blood/plasma concentration -time data are available in absence of tissue sampling, as in the clinical situation. Thus, the more important application of the model is in the defi nition of drug distribution kinetics. The circulatory model is based on TTD on inverse of Laplace transform, and may be used only under linear conditions. Saturable systems cannot be defi ned by this method. Accommodation of heterogeneous enzyme or transporter distribution to the circulatory model within an organ has not been tried.
Fractal models are rarely employed, but have defi nite usefulness in terms of describing distribution phenomena and kinetics/dynamics. Homogeneity is a presupposition typically considered in compartmental modeling, but is a departure of reality. However, the physiological implications of the fractal concepts are serious since fractal structures and processes are ubiquitous in living things, eg, the lung, the vascular system, and the distribution of blood fl ow through the blood vessels. Accordingly, fractal models are used when classical kinetics have been found to be unsatisfactory under dimensional constraints, eg, phase boundaries, understirred media or membrane reactions. When homogeneity cannot be applied to the structure of the organ, or when non-Fickian diffusion occurs, then fractal kinetics is more appropriate. Fractal models are plausible explanations for deviation from MM kinetics, and time-dependent coefficients derived from fractal considerations may be used to describe the nonlinear phenomenon. Overall, fractal models provide the basis for the incorporation of various heterogeneous approaches to systems where the homogeneous approaches are not suffi cient to describe the system.
These advanced models are intrinsically very different. The easiest to consider in terms of mass balanced equations is the PBPK model and their heterogeneous counterparts. For circulatory models, vascular mixing may be attributed to mechanical dispersion in the microcirculatory network and result in appropriate transit time distribution. The concepts derived from fractal geometry and fractal kinetics can be used to achieve a more realistic modeling of the complex and the kinetically heterogeneous phenomena. There re mains to be a lot more to be learned about these advanced models.
